Exploratory Cross-sectional Study of Associations between Fatty Acid Metabolism Scintigraphy (123I-BMIPP test) in the Liver of Nonalcoholic Fatty Liver Disease (NAFLD) Patients and Serum Biomarkers and the Degree of Progression of NAFLD Pathology

Exploratory Cross-sectional Study of Associations between Fatty Acid Metabolism Scintigraphy (123I-BMIPP test) in the Liver of Nonalcoholic Fatty Liver Disease (NAFLD) Patients and Serum Biomarkers and the Degree of Progression of NAFLD Pathology - Exploratory Cross-sectional Study of Associations between Fatty Acid Metabolism Scintigraphy (123I-BMIPP test) in the Liver of Nonalcoholic Fatty Liver Disease (NAFLD) Patients and Serum Biomarkers and the Degree of Progression of NAFLD Pathology

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009841

Enrollment

Registered

2013-02-01

Start date

2013-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease

Interventions

We will perform fatty acid scintigraphy (123I-BMIPP test).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: NAFLD patients Patients with a pathological diagnosis of NAFLD based on a liver biopsy within the past 8 weeks Patients from whom consent has been obtained to participate in this study, which has been approved by the ethics committee.

Exclusion criteria

Exclusion criteria: a. Patients who have any other liver disease, such as chronic hepatitis C, chronic hepatitis B (HBs-Ag-positive patients), autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, &#61537;1-antitrypsin deficiency, Wilson disease, or alcohol-related liver disease b. Patients who have a serious hepatic dysfunction, liver failure (encephalopathy, ascites, ruptured varices, or hyperbilirubinemia) c. Patients who have a serious renal dysfunction d. Patients who have a serious cardiopulmonary dysfunction e. Pregnant women, parturient women, breast-feeding women

Design outcomes

Primary

Measure	Time frame
We will conduct this study by performing fatty acid scintigraphy in NAFLD patients grouped according to the degree of histopathological progression in the liver and make comparisons between the degrees of BMIPP uptake in the various groups.	—

Secondary

Measure	Time frame
We will comprehensively analyze each factor involved in fatty acid metabolism in each group by using blood serum collected in the fasting state, after a meal, and during fatty acid scintigraphy, and liver tissue. Then we assess their relationships with the disease status.	—

Countries

Japan

Contacts

Public ContactYuichi Nozaki

National Center for Global Health and Medicine Department of Gastroenterology

03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026